APM
Aptorum Group Ltd
$1.01
-7.34%
$8.9M
No data for this timeframe.
Vol
Market Cap$8.9M
Cap SizeNano Cap
SEC Reports3
Press Releases1
Recent Activity
Jun 4, 2026
SEC
The SEC declared effective Aptorum Group's shelf registration (File No. 333-291593) on June 3, 2026, under the 1933 Act.
EFFECT — Impact 3/10
May 14, 2026
SEC
Aptorum Group filed Pre-Effective Amendment No. 4 to its S-4 registration statement, providing the definitive proxy stat
6-K — Impact 7/10
Apr 28, 2026
earnings_calendar
APM Q4 2025 Earnings After Market Close — 2026-04-28
Mar 27, 2026
SEC
Aptorum Group Ltd (APM) is a clinical-stage biopharmaceutical company with no revenue, significant losses, and an audito
20-F — Impact 7/10
Mar 6, 2026
Press
Aptorum Group Ltd (APM) received a Nasdaq delisting notice due to its share price falling below $1, triggering a 180-day
Impact 6/10
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
EFFECT
3/10
The SEC declared effective Aptorum Group's shelf registration (File No. 333-291593) on June 3, 2026, under the 1933 Act.
Jun 4, 2026
BEARISH
6-K
7/10
Aptorum Group filed Pre-Effective Amendment No. 4 to its S-4 registration statement, providing the definitive proxy stat
May 14, 2026
BEARISH
Press
6/10
Aptorum Group Ltd (APM) received a Nasdaq delisting notice due to its share price falling below $1, triggering a 180-day
Mar 6, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
NEUTRAL
EFFECT
3/10
The SEC declared effective Aptorum Group's shelf registration (File No. 333-291593) on June 3, 2026,
Jun 4, 2026
BEARISH
6-K
7/10
Aptorum Group filed Pre-Effective Amendment No. 4 to its S-4 registration statement, providing the d
May 14, 2026
BEARISH
20-F
7/10
Aptorum Group Ltd (APM) is a clinical-stage biopharmaceutical company with no revenue, significant l
Mar 27, 2026
Historical analyst distribution: 83% buy across 6 analysts — 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2023 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Aug 1, 2023 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jul 1, 2023 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jun 1, 2023 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 28, 2026
earnings_calendar
APM Q4 2025 Earnings After Market Close — 2026-04-28
Mar 6, 2026
announcement
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
<p>Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has r